NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,522,329 | -39.4% | 320,907 | -23.0% | 0.00% | – |
| Q2 2023 | $4,161,964 | -48.0% | 416,613 | -53.7% | 0.00% | – |
| Q1 2023 | $7,996,334 | -27.4% | 900,488 | -10.3% | 0.00% | -100.0% |
| Q4 2022 | $11,020,000 | -49.8% | 1,003,643 | -40.5% | 0.00% | -50.0% |
| Q3 2022 | $21,964,000 | -3.2% | 1,685,651 | -5.9% | 0.00% | 0.0% |
| Q2 2022 | $22,688,000 | +44.3% | 1,790,655 | +59.6% | 0.00% | +100.0% |
| Q1 2022 | $15,720,000 | -51.0% | 1,122,023 | +1.3% | 0.00% | -50.0% |
| Q4 2021 | $32,080,000 | +62.6% | 1,108,103 | +68.2% | 0.00% | 0.0% |
| Q3 2021 | $19,732,000 | +12.9% | 658,617 | 0.0% | 0.00% | +100.0% |
| Q2 2021 | $17,473,000 | -2.9% | 658,617 | +13.7% | 0.00% | -50.0% |
| Q1 2021 | $18,004,000 | +63.1% | 579,085 | +72.5% | 0.00% | +100.0% |
| Q4 2020 | $11,037,000 | -5.8% | 335,685 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,719,000 | – | 335,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |